Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Receives $52.33 Consensus Target Price from Analysts

Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) have been assigned a consensus rating of “Moderate Buy” from the eight brokerages that are presently covering the firm, MarketBeat.com reports. Four analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $52.33.

Several research firms have recently commented on AGIO. Leerink Partnrs downgraded shares of Agios Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Friday, September 27th. Royal Bank of Canada reissued an “outperform” rating and issued a $55.00 price objective on shares of Agios Pharmaceuticals in a report on Friday, November 1st. Raymond James reissued an “outperform” rating and set a $51.00 target price on shares of Agios Pharmaceuticals in a research note on Thursday, October 10th. Scotiabank increased their price objective on Agios Pharmaceuticals from $51.00 to $53.00 and gave the company a “sector outperform” rating in a research note on Friday, November 1st. Finally, Leerink Partners cut Agios Pharmaceuticals from an “outperform” rating to a “market perform” rating and lowered their target price for the stock from $60.00 to $56.00 in a report on Friday, September 27th.

Insiders Place Their Bets

In other Agios Pharmaceuticals news, CFO Cecilia Jones sold 2,542 shares of the business’s stock in a transaction dated Thursday, September 26th. The shares were sold at an average price of $49.03, for a total transaction of $124,634.26. Following the sale, the chief financial officer now directly owns 20,158 shares in the company, valued at $988,346.74. This represents a 11.20 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 4.93% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Acadian Asset Management LLC acquired a new position in shares of Agios Pharmaceuticals during the second quarter worth about $37,000. Quest Partners LLC acquired a new position in shares of Agios Pharmaceuticals in the 2nd quarter valued at $40,000. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Agios Pharmaceuticals by 21.4% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,058 shares of the biopharmaceutical company’s stock valued at $94,000 after buying an additional 363 shares during the last quarter. CWM LLC raised its stake in Agios Pharmaceuticals by 554.7% during the 3rd quarter. CWM LLC now owns 2,167 shares of the biopharmaceutical company’s stock valued at $96,000 after acquiring an additional 1,836 shares during the last quarter. Finally, Quantbot Technologies LP purchased a new stake in shares of Agios Pharmaceuticals during the third quarter worth approximately $146,000.

Agios Pharmaceuticals Stock Performance

Agios Pharmaceuticals stock opened at $52.89 on Friday. Agios Pharmaceuticals has a fifty-two week low of $20.96 and a fifty-two week high of $62.58. The business’s 50-day simple moving average is $46.62 and its two-hundred day simple moving average is $44.07. The company has a market cap of $3.02 billion, a PE ratio of 4.66 and a beta of 0.75.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.